An AI-generated illustration depicting Zaynich's FDA approval.
India’s reputation as the “Pharmacy of the World” has been significantly enhanced by the success of Zaynich, an indigenously developed breakthrough intravenous antibiotic designed to combat multidrug-resistant ''superbugs”.
In a landmark achievement, the Indian-manufactured drug has received approval from the US Food and Drug Administration (FDA), elevating India’s status from a leading producer of generic medicines to a global pharmaceutical innovator.
The breakthrough underscores not only India’s growing capabilities in complex research and development (R&D) but also its strength in intellectual property generation. Developed by pharmaceutical company, Wockhardt, Zaynich demonstrates the country’s ability to discover, develop and commercialise novel drugs.
By producing a new chemical entity capable of addressing the global health crisis posed by antimicrobial resistance, India’s biotechnology sector has established itself as a key player in tackling some of the world’s most pressing and unresolved medical challenges.
